AIM ImmunoTech Inc is trading 86.2% down at $0.38 as investors react to a heavily dilutive financing and compliance-driven restructuring of its capital structure.
- The company recently issued a large volume of equity and warrants in a move to regain NYSE American listing compliance.
- The market is currently digesting a sharply increased share count, which has triggered an ~85% collapse and sustained selling pressure.